Clinical Trials Browser

Terminated × Gemcitabine × Gynecologic × Clear all

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Terminated

6 enrolled 3 charts

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00421096 2026-03-13

GEMCOL

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

GynecologicSarcoma

Advanced Endometrial Cancer

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Phase 2 Terminated

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01279291 2024-04-26

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Phase 1 Terminated

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1/2 Terminated

7 enrolled 6 charts

Ovarian Neoplasms

NCT03386721 2023-02-21

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Phase 2 Terminated

256 enrolled 26 charts

Uterine Cervical Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3 Terminated

Ovarian Neoplasms

NCT00910000 2018-09-10

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Phase 1/2 Terminated

15 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01936974 2018-02-20

PGA

Phase 2 Terminated

7 enrolled 1 chart

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00312650 2015-01-12

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Phase 2 Terminated

Ovarian Neoplasms, Recurrence

NCT00418093 2014-06-19

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Phase 2 Terminated

19 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003378 2013-07-09

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Phase 1 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003382 2013-06-10

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Phase 1 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00583622 2013-05-21

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Phase 2 Terminated

13 enrolled 5 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006224 2013-04-11

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT00006482 2013-04-11

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT01016054 2013-02-27

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Phase 1 Terminated

Carcinoma, Ovarian Diseases, Ovarian Neoplasms

NCT00051584 2011-10-24

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Phase 2 Terminated

Ovarian Neoplasms

NCT00055432 2006-09-15

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Phase 2 Terminated

Ovarian Neoplasms